1. Scrip
  2. >>Partnered Content

Achieving Firsts In Biosimilars From China

 
• By Andrew Warmington

Explore this insightful article and exclusive video with Henlius’ COO to discover:

  • Its achievements in biosimilar approvals, including serplulimab, and its anticipated launch into the European market.
  • The essential role of strategic partnerships in Henlius’ success, including over 20 global collaborations with Abbott Laboratories, Accord Healthcare, Eurofarma and more.
  • An overview of Henlius’ late-stage pipeline drugs, and ambitious plans shaping the future of biosimilars.

Click here to download this Special Report in PDF format


More from Partnered Content

Sponsored by :

Podcast: Beyond The Checkpoint — Next-Gen Strategies In Immuno-Oncology

As the immuno-oncology landscape evolves, developers are facing new challenges in early-phase design, differentiation, and regulatory alignment — all while advancing increasingly complex modalities.

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

Sponsored by

How Olon’s fully integrated, end-to-end ADC capabilities drive quality and scale

Hear experts Matthieu Culié and Alessandro Agosti as they discuss how Olon stands out in a competitive landscape through its fully integrated end-to-end ADC manufacturing expertise, global operations, impurity control and strategic facilities.

Sponsored by :

Adalvo: Exploring European B2B Pharma’s Next Steps

Listen now as Citeline speaks with Anil Okay, CEO of Europe’s fast-growing pharma B2B, Adalvo. Learn what the company’s recent acquisition by private equity firm EQT means for both Adalvo and for the industry at large, and find out what trends will be fueling pharma in the years ahead.

More from Leadership

Sponsored by :

Podcast: Beyond The Checkpoint — Next-Gen Strategies In Immuno-Oncology

As the immuno-oncology landscape evolves, developers are facing new challenges in early-phase design, differentiation, and regulatory alignment — all while advancing increasingly complex modalities.

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

Sponsored by

How Olon’s fully integrated, end-to-end ADC capabilities drive quality and scale

Hear experts Matthieu Culié and Alessandro Agosti as they discuss how Olon stands out in a competitive landscape through its fully integrated end-to-end ADC manufacturing expertise, global operations, impurity control and strategic facilities.